Home Tirzepatide Side effects Vomiting
Tirzepatide and Vomiting
Roughly 8–13% of participants — less common than nausea and more likely at higher doses and after rapid escalation.
Roughly 8–13% of participants of participants in the tirzepatide trial program reported vomiting — less common than nausea and more likely at higher doses and after rapid escalation.
The same delayed gastric emptying that produces nausea can tip into vomiting when meal volume, fat content or alcohol overwhelm a slowed stomach. Clusters in the days after a dose increase. Persistent vomiting at a stable dose is not expected and warrants review.
Frequencies are approximate ranges from the published trial program and differ by dose, population and how events were collected. They are not a prediction for any individual.
| Reported frequency | Roughly 8–13% of participants |
|---|---|
| Typical onset | Clusters in the days after a dose increase. Persistent vomiting at a stable dose is not expected and warrants review. |
| Mechanism | The same delayed gastric emptying that produces nausea can tip into vomiting when meal volume, fat content or alcohol overwhelm a slowed stomach. |
| Usually resolves | Yes, with adaptation or management |
| Requires urgent review | Only if a red-flag symptom below is present |
Why tirzepatide causes vomiting
The same delayed gastric emptying that produces nausea can tip into vomiting when meal volume, fat content or alcohol overwhelm a slowed stomach.
When vomiting starts and how long it lasts
Clusters in the days after a dose increase. Persistent vomiting at a stable dose is not expected and warrants review.
How to manage vomiting on tirzepatide
- Reduce meal size substantially and eat more slowly
- Avoid high-fat meals and alcohol around injection days
- Prioritize fluid and electrolyte replacement
- Ask about holding or reducing the dose rather than pushing through
- Do not skip and double doses to compensate for a missed week
Vomiting: when to contact a clinician
Seek medical advice promptly if any of the following occurs:
- Inability to keep fluids down for 24 hours
- Vomiting with severe abdominal pain radiating to the back
- Signs of dehydration, confusion or fainting
Does vomiting mean the tirzepatide dose is wrong?
Not necessarily. Adverse effects on tirzepatide cluster in the days after a dose increase and typically settle as the gut adapts. The usual response to a poorly tolerated step is to hold the current strength for another four weeks rather than to stop treatment or to climb faster. That decision belongs to your prescriber.
Frequently asked questions
Should I stop if I vomit once?
One episode after a dose step is common. Repeated vomiting is a reason to contact your prescriber.
Does vomiting mean I will lose more weight?
No, and it raises dehydration and electrolyte risk. It is a signal to slow the titration.
People also ask about tirzepatide vomiting
What is tirzepatide vomiting?
Tirzepatide vomiting is covered in full on this page, with the clinical detail drawn from the tirzepatide prescribing information and the published SURMOUNT and SURPASS trial program, and any price figures drawn from our tracked dataset and dated to their last verification.
Does tirzepatide vomiting apply to compounded tirzepatide as well as Zepbound?
The molecule is the same, so the clinical content applies to both. What differs is regulatory status, dose metering and price: compounded preparations are not FDA-approved, arrive as a multi-dose vial you measure yourself, and cost a fraction of the brand routes.
How much does tirzepatide vomiting cost per month in 2026?
Compounded tirzepatide runs from $133 per month at the entry dose across the 21 compounded programs we track. At a 10 mg maintenance dose the cheapest tracked route is Oak Longevity at $199 per month, or about $2,388 for a first year on the standard escalation. Brand Zepbound through manufacturer self-pay sits well above that and pharmacy retail well above again. Verified 2026-08-05.
Is tirzepatide vomiting FDA-approved?
Brand tirzepatide (Zepbound and Mounjaro) is FDA-approved. Compounded tirzepatide is not: FDA does not approve compounded drugs and does not review them for safety, effectiveness or quality before they are marketed. The active molecule is the same; the regulatory review is not.
Sources
- US prescribing information for tirzepatide (Zepbound and Mounjaro), Eli Lilly and Company — dosing, storage, warnings and contraindications.
- SURMOUNT-1 — tirzepatide once weekly for the treatment of obesity, NCT04184622.
- SURPASS-2 — tirzepatide versus semaglutide 1 mg in type 2 diabetes, NCT03987919.
- Full source ledger — every primary source with a live link, what it supports, the date we read it, and the claims we deliberately do not source.